α1-Antitrypsin deficiency associated with increased risk of heart failure
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
α1-Antitrypsin deficiency associated with increased risk of heart failure. / Winther, Sine V.; Landt, Eskild M.; Nordestgaard, Børge G.; Seersholm, Niels; Dahl, Morten.
I: ERJ Open Research, Bind 9, Nr. 5, 00319-2023, 2023.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - α1-Antitrypsin deficiency associated with increased risk of heart failure
AU - Winther, Sine V.
AU - Landt, Eskild M.
AU - Nordestgaard, Børge G.
AU - Seersholm, Niels
AU - Dahl, Morten
N1 - Publisher Copyright: © The authors 2023.
PY - 2023
Y1 - 2023
N2 - Background Individuals with α1-antitrypsin deficiency have increased elastase activity resulting in continuous degradation of elastin and early onset of COPD. Increased elastase activity may also affect elastic properties of the heart, which may impact risk of heart failure. We tested the hypothesis that α1-antitrypsin deficiency is associated with increased risk of heart failure in two large populations. Methods In a nationwide nested study of 2209 patients with α1-antitrypsin deficiency and 21 869 controls without α1-antitrypsin deficiency matched on age, sex and municipality, we recorded admissions and deaths due to heart failure during a median follow-up of 62 years. We also studied a population-based cohort of another 102 481 individuals from the Copenhagen General Population Study including 187 patients from the Danish α1-Antitrypsin Deficiency Registry, all with genetically confirmed α1-antitrypsin deficiency. Results Individuals with versus without α1-antitrypsin deficiency had increased risk of heart failure hospitalisation in the nationwide cohort (adjusted hazard ratio 2.64, 95% CI 2.25–3.10) and in the population-based cohort (1.77, 95% CI 1.14–2.74). Nationwide, these hazard ratios were highest in those without myocardial infarction (3.24, 95% CI 2.70–3.90), without aortic valve stenosis (2.80, 95% CI 2.38– 3.29), without hypertension (3.44, 95% CI 2.81–4.22), without atrial fibrillation (3.33, 95% CI 2.75–4.04) and without any of these four diseases (6.00, 95% CI 4.60–7.82). Hazard ratios for heart failure-specific mortality in individuals with versus without α1-antitrypsin deficiency were 2.28 (95% CI 1.57–3.32) in the nationwide cohort and 3.35 (95% CI 1.04–10.74) in the population-based cohort. Conclusion Individuals with α1-antitrypsin deficiency have increased risk of heart failure hospitalisation and heart failure-specific mortality in the Danish population.
AB - Background Individuals with α1-antitrypsin deficiency have increased elastase activity resulting in continuous degradation of elastin and early onset of COPD. Increased elastase activity may also affect elastic properties of the heart, which may impact risk of heart failure. We tested the hypothesis that α1-antitrypsin deficiency is associated with increased risk of heart failure in two large populations. Methods In a nationwide nested study of 2209 patients with α1-antitrypsin deficiency and 21 869 controls without α1-antitrypsin deficiency matched on age, sex and municipality, we recorded admissions and deaths due to heart failure during a median follow-up of 62 years. We also studied a population-based cohort of another 102 481 individuals from the Copenhagen General Population Study including 187 patients from the Danish α1-Antitrypsin Deficiency Registry, all with genetically confirmed α1-antitrypsin deficiency. Results Individuals with versus without α1-antitrypsin deficiency had increased risk of heart failure hospitalisation in the nationwide cohort (adjusted hazard ratio 2.64, 95% CI 2.25–3.10) and in the population-based cohort (1.77, 95% CI 1.14–2.74). Nationwide, these hazard ratios were highest in those without myocardial infarction (3.24, 95% CI 2.70–3.90), without aortic valve stenosis (2.80, 95% CI 2.38– 3.29), without hypertension (3.44, 95% CI 2.81–4.22), without atrial fibrillation (3.33, 95% CI 2.75–4.04) and without any of these four diseases (6.00, 95% CI 4.60–7.82). Hazard ratios for heart failure-specific mortality in individuals with versus without α1-antitrypsin deficiency were 2.28 (95% CI 1.57–3.32) in the nationwide cohort and 3.35 (95% CI 1.04–10.74) in the population-based cohort. Conclusion Individuals with α1-antitrypsin deficiency have increased risk of heart failure hospitalisation and heart failure-specific mortality in the Danish population.
U2 - 10.1183/23120541.00319-2023
DO - 10.1183/23120541.00319-2023
M3 - Journal article
C2 - 37753284
AN - SCOPUS:85172933521
VL - 9
JO - ERJ Open Research
JF - ERJ Open Research
SN - 2312-0541
IS - 5
M1 - 00319-2023
ER -
ID: 387831708